User Manual Part 4

CLINICAL STUDY - DECREASE HF
C-5
Tab le C-2. DECREASE-HF study patient characteristics (continued)
Characteristic
Measurement
LV-CRT
(N=101)
LV Offset
(N=104)
BiV-CRT
(N=101)
P-value
a
LVEF (%)
N 101 104 100
Mean ± SD
22.6 ± 6.6 22.4 ± 6.7 23.2 ± 7.1 0.67
Range 8.0 - 35.0 9.0 - 35.0 5.0 - 35.0
QRS Duration (ms)
N 101 104 101
Mean ± SD
165 ± 15 167 ± 16 168 ± 15 0.29
Range 150 - 220 150 - 220 150 - 218
PR Inte rval (ms)
N 101 104 101
Mean ± SD
195 ± 42 195 ± 42 194 ± 39 0.98
Range 120 - 318 100 - 320 88 - 320
P-Wave Duration (ms)
N 101 104 101
Mean ± SD
91 ± 22 96 ± 22 95 ± 24 0.21
Range 39 - 140 40 - 140 40 - 145
Concomitant Medications
b
[N
(%)]
ACE Inhibitor/ARB 88 (8 7) 88 (85) 91 (90)
0.50
Beta Blocker
84 (8 3) 84 (81) 82 (81)
0.89
Digoxin
47 (4 7) 55 (53) 46 (46)
0.52
Diuretic
89 (8 8) 93 (89) 82 (81)
0.19
Loop D iuretic
87 (8 6) 91 (88) 80 (79)
0.22
Nonloop Diuretic
8(8) 8(8) 8(8)
1.00
Aldosterone Antagonist
40 (4 0) 37 (36) 40 (40)
0.79
Antiarrhythmic
21 (2 1) 14 (13) 13 (13)
0.22
Etiology [N (%)]
Ischemic
67 (6 6) 70 (67) 58 (57)
0.27
Nonischemic
34 (3 4) 34 (33) 43 (43)
Conduction Disorder [N (% )] Left Bundle B ran ch
Block
94 (9 3) 95 (91) 97 (96)
0.68
Nonspecific
Intraventricular
Conduction
6(6) 8(8) 4(4)
Right Bundle Branch
Block
1(1) 1(1) 0(0)
a. P-values for continuous variables were calculated from a Student’s t-test; p-values for discrete variables were calculated from
a Chi-squared test.
b. Patients may appear in more than one category.
- DRAFT -